Abstract:
In order to improve treatment efficacy for patients with diabetes mellitus the possibility of administration of Zinkit (Woerwag Pharma, Germany) in a complex treatment program was studied. According to the results of a complex assessment of glycemia control indices in patients with diabetes mellitus 3 weeks after the enrollment to the study it was revealed, that additional to hypoglycemic therapy administration of zinc-containing edication not only promoted reliable decrease of fasting and 2-hours postprandial blood glucose level, but also approached glycemia indices to the goal levels of a satisfactory control of diabetes, provided significant reduction of HbA1C level by 6,8 % of its initial level.
